Moderna (Seite 68)
eröffnet am 24.11.19 21:27:56 von
neuester Beitrag 05.05.23 10:23:01 von
neuester Beitrag 05.05.23 10:23:01 von
Beiträge: 1.856
ID: 1.315.946
ID: 1.315.946
Aufrufe heute: 0
Gesamt: 274.456
Gesamt: 274.456
Aktive User: 0
ISIN: US60770K1079 · WKN: A2N9D9 · Symbol: MRNA
101,02
EUR
+2,06 %
+2,04 EUR
Letzter Kurs 16:22:25 Tradegate
Neuigkeiten
| Moderna Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
25.04.24 · Accesswire  |
24.04.24 · Accesswire |
22.04.24 · Accesswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 22,950 | +19,22 | |
| 0,5250 | +19,08 | |
| 1,9700 | +15,20 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 11,820 | -12,18 | |
| 8,0100 | -12,85 | |
| 1,9500 | -25,14 | |
| 1,6052 | -30,21 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
Die ganzen Short Angriffe nerven tierisch...
kann es sein, dass Moderna im Jan dann auch in D verimpft wird?
Das hört sich doch sehr vielversprechend für diese Woche (FDA-Entscheid) an:
Moderna (MRNA) – Moderna said some documents related to the submission of its Covid-19 vaccine candidate for European approval were accessed in a cyberattack on the European Medicines Agency. The drugmaker said the documents did not identify any individual study participants. Separately, the Food and Drug Administration said Moderna’s Covid vaccine data meets expectations for emergency use.
Übersetzung des letzten Teils:
Unabhängig davon, sagte die Food and Drug Administration, dass die Covid-Impfstoffdaten von Moderna die Erwartungen für den Notfall erfüllen.
Quelle:
https://www.cnbc.com/2020/12/15/stocks-making-the-biggest-mo…
Moderna (MRNA) – Moderna said some documents related to the submission of its Covid-19 vaccine candidate for European approval were accessed in a cyberattack on the European Medicines Agency. The drugmaker said the documents did not identify any individual study participants. Separately, the Food and Drug Administration said Moderna’s Covid vaccine data meets expectations for emergency use.
Übersetzung des letzten Teils:
Unabhängig davon, sagte die Food and Drug Administration, dass die Covid-Impfstoffdaten von Moderna die Erwartungen für den Notfall erfüllen.
Quelle:
https://www.cnbc.com/2020/12/15/stocks-making-the-biggest-mo…
Dann hoffe ich mal auf eine grüne Woche und das alles glatt läuft!
Kuriose Kaufempfehlung.
https://www.4investors.de/nachrichten/mobile/boerse.php?sekt…
https://www.4investors.de/nachrichten/mobile/boerse.php?sekt…
Trading Spotlight
Antwort auf Beitrag Nr.: 66.047.237 von michi140671 am 13.12.20 08:07:43Die muss noch warten, erst wen sie bei der FDA positiv durch ist, kommt sie in die Auswahl. das kann noch gehen
Antwort auf Beitrag Nr.: 66.047.237 von michi140671 am 13.12.20 08:07:43Ich denke, das hat nicht geklappt. Folgendes wurde im Biontech Forum geposted:
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The following 100 securities will be added to the Index:
EXCHANGE SYMBOL COMPANY NAME
Nasdaq ABUS Arbutus Biopharma Corporation
Nasdaq ADAP Adaptimmune Therapeutics plc
Nasdaq AKUS Akouos, Inc.
Nasdaq ALT Altimmune, Inc.
Nasdaq ALVR AlloVir, Inc.
Nasdaq ALXO ALX Oncology Holdings Inc.
Nasdaq AMTI Applied Molecular Transport Inc.
Nasdaq ANNX Annexon, Inc.
Nasdaq APLT Applied Therapeutics, Inc.
Nasdaq APRE Aprea Therapeutics, Inc.
Nasdaq ARCT Arcturus Therapeutics Holdings Inc.
Nasdaq ARQT Arcutis Biotherapeutics, Inc.
Nasdaq AVDL Avadel Pharmaceuticals plc
Nasdaq AZN AstraZeneca PLC
Nasdaq BDTX Black Diamond Therapeutics, Inc.
Nasdaq BEAM Beam Therapeutics Inc.
Nasdaq BNTX BioNTech SE
Nasdaq CABA Cabaletta Bio, Inc.
Nasdaq CALA Calithera Biosciences, Inc.
Nasdaq CDXS Codexis, Inc.
Nasdaq CLVS Clovis Oncology, Inc.
Nasdaq CNCE Concert Pharmaceuticals, Inc.
Nasdaq CNST Constellation Pharmaceuticals, Inc.
Nasdaq CRNX Crinetics Pharmaceuticals, Inc.
Nasdaq CRTX Cortexyme, Inc.
Nasdaq FMTX Forma Therapeutics Holdings, Inc.
Nasdaq FPRX Five Prime Therapeutics, Inc.
Nasdaq FREQ Frequency Therapeutics, Inc.
Nasdaq FULC Fulcrum Therapeutics, Inc.
Nasdaq FUSN Fusion Pharmaceuticals Inc.
Nasdaq GBIO Generation Bio Co.
Nasdaq GMDA Gamida Cell Ltd.
Nasdaq HARP Harpoon Therapeutics, Inc.
Nasdaq IDYA IDEAYA Biosciences, Inc.
Nasdaq IGMS IGM Biosciences, Inc.
Nasdaq IMAB I-MAB
Nasdaq IMUX Immunic, Inc.
Nasdaq IMVT Immunovant, Inc.
Nasdaq INZY Inozyme Pharma, Inc.
Nasdaq ISEE IVERIC bio, Inc.
Nasdaq ITOS iTeos Therapeutics, Inc.
Nasdaq JNCE Jounce Therapeutics, Inc.
Nasdaq KALA Kala Pharmaceuticals, Inc.
Nasdaq KALV KalVista Pharmaceuticals, Inc.
Nasdaq KDMN Kadmon Holdings, Inc.
Nasdaq KDNY Chinook Therapeutics, Inc.
Nasdaq KLDO Kaleido Biosciences, Inc.
Nasdaq KMDA Kamada Ltd.
Nasdaq KNSA Kiniksa Pharmaceuticals, Ltd.
Nasdaq KROS Keros Therapeutics, Inc.
Nasdaq KRYS Krystal Biotech, Inc.
Nasdaq KZR Kezar Life Sciences, Inc.
Nasdaq LEGN Legend Biotech Corporation
Nasdaq LRMR Larimar Therapeutics, Inc.
Nasdaq MDGL Madrigal Pharmaceuticals, Inc.
Nasdaq MNOV MediciNova, Inc.
Nasdaq MRNS Marinus Pharmaceuticals, Inc.
Nasdaq MRSN Mersana Therapeutics, Inc.
Nasdaq NK NantKwest, Inc.
Nasdaq NKTX Nkarta, Inc.
Nasdaq NLTX Neoleukin Therapeutics, Inc.
Nasdaq NRIX Nurix Therapeutics, Inc.
Nasdaq NVAX Novavax, Inc.
Nasdaq NXTC NextCure, Inc.
Nasdaq OCUL Ocular Therapeutix, Inc.
Nasdaq ODT Odonate Therapeutics, Inc.
Nasdaq ORIC Oric Pharmaceuticals, Inc.
Nasdaq OVID Ovid Therapeutics Inc.
Nasdaq PAHC Phibro Animal Health Corporation
Nasdaq PAND Pandion Therapeutics Inc.
Nasdaq PASG Passage Bio, Inc.
Nasdaq PCVX Vaxcyte, Inc.
Nasdaq PLRX Pliant Therapeutics, Inc.
Nasdaq PRTK Paratek Pharmaceuticals, Inc.
Nasdaq PRVB Provention Bio, Inc.
Nasdaq PSTX Poseida Therapeutics, Inc.
Nasdaq RAPT RAPT Therapeutics, Inc.
Nasdaq RDHL Redhill Biopharma Ltd.
Nasdaq REPL Replimune Group, Inc.
Nasdaq RLAY Relay Therapeutics, Inc.
Nasdaq RLMD Relmada Therapeutics, Inc.
Nasdaq RNA Avidity Biosciences, Inc.
Nasdaq RPRX Royalty Pharma plc
Nasdaq RPTX Repare Therapeutics Inc.
Nasdaq RVMD Revolution Medicines, Inc.
Nasdaq SELB Selecta Biosciences, Inc.
Nasdaq SMMT Summit Therapeutics Inc.
Nasdaq SNDX Syndax Pharmaceuticals, Inc.
Nasdaq SPRO Spero Therapeutics, Inc.
Nasdaq STRO Sutro Biopharma, Inc.
Nasdaq SURF Surface Oncology, Inc.
Nasdaq SWTX SpringWorks Therapeutics, Inc.
Nasdaq TCRR TCR2 Therapeutics Inc.
Nasdaq VIE Viela Bio, Inc.
Nasdaq VIR Vir Biotechnology, Inc.
Nasdaq VSTM Verastem, Inc.
Nasdaq VYNE VYNE Therapeutics Inc.
Nasdaq XENE Xenon Pharmaceuticals Inc.
Nasdaq ZIOP ZIOPHARM Oncology Inc
Nasdaq ZNTL Zentalis Pharmaceuticals, Inc.
NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The following 100 securities will be added to the Index:
EXCHANGE SYMBOL COMPANY NAME
Nasdaq ABUS Arbutus Biopharma Corporation
Nasdaq ADAP Adaptimmune Therapeutics plc
Nasdaq AKUS Akouos, Inc.
Nasdaq ALT Altimmune, Inc.
Nasdaq ALVR AlloVir, Inc.
Nasdaq ALXO ALX Oncology Holdings Inc.
Nasdaq AMTI Applied Molecular Transport Inc.
Nasdaq ANNX Annexon, Inc.
Nasdaq APLT Applied Therapeutics, Inc.
Nasdaq APRE Aprea Therapeutics, Inc.
Nasdaq ARCT Arcturus Therapeutics Holdings Inc.
Nasdaq ARQT Arcutis Biotherapeutics, Inc.
Nasdaq AVDL Avadel Pharmaceuticals plc
Nasdaq AZN AstraZeneca PLC
Nasdaq BDTX Black Diamond Therapeutics, Inc.
Nasdaq BEAM Beam Therapeutics Inc.
Nasdaq BNTX BioNTech SE
Nasdaq CABA Cabaletta Bio, Inc.
Nasdaq CALA Calithera Biosciences, Inc.
Nasdaq CDXS Codexis, Inc.
Nasdaq CLVS Clovis Oncology, Inc.
Nasdaq CNCE Concert Pharmaceuticals, Inc.
Nasdaq CNST Constellation Pharmaceuticals, Inc.
Nasdaq CRNX Crinetics Pharmaceuticals, Inc.
Nasdaq CRTX Cortexyme, Inc.
Nasdaq FMTX Forma Therapeutics Holdings, Inc.
Nasdaq FPRX Five Prime Therapeutics, Inc.
Nasdaq FREQ Frequency Therapeutics, Inc.
Nasdaq FULC Fulcrum Therapeutics, Inc.
Nasdaq FUSN Fusion Pharmaceuticals Inc.
Nasdaq GBIO Generation Bio Co.
Nasdaq GMDA Gamida Cell Ltd.
Nasdaq HARP Harpoon Therapeutics, Inc.
Nasdaq IDYA IDEAYA Biosciences, Inc.
Nasdaq IGMS IGM Biosciences, Inc.
Nasdaq IMAB I-MAB
Nasdaq IMUX Immunic, Inc.
Nasdaq IMVT Immunovant, Inc.
Nasdaq INZY Inozyme Pharma, Inc.
Nasdaq ISEE IVERIC bio, Inc.
Nasdaq ITOS iTeos Therapeutics, Inc.
Nasdaq JNCE Jounce Therapeutics, Inc.
Nasdaq KALA Kala Pharmaceuticals, Inc.
Nasdaq KALV KalVista Pharmaceuticals, Inc.
Nasdaq KDMN Kadmon Holdings, Inc.
Nasdaq KDNY Chinook Therapeutics, Inc.
Nasdaq KLDO Kaleido Biosciences, Inc.
Nasdaq KMDA Kamada Ltd.
Nasdaq KNSA Kiniksa Pharmaceuticals, Ltd.
Nasdaq KROS Keros Therapeutics, Inc.
Nasdaq KRYS Krystal Biotech, Inc.
Nasdaq KZR Kezar Life Sciences, Inc.
Nasdaq LEGN Legend Biotech Corporation
Nasdaq LRMR Larimar Therapeutics, Inc.
Nasdaq MDGL Madrigal Pharmaceuticals, Inc.
Nasdaq MNOV MediciNova, Inc.
Nasdaq MRNS Marinus Pharmaceuticals, Inc.
Nasdaq MRSN Mersana Therapeutics, Inc.
Nasdaq NK NantKwest, Inc.
Nasdaq NKTX Nkarta, Inc.
Nasdaq NLTX Neoleukin Therapeutics, Inc.
Nasdaq NRIX Nurix Therapeutics, Inc.
Nasdaq NVAX Novavax, Inc.
Nasdaq NXTC NextCure, Inc.
Nasdaq OCUL Ocular Therapeutix, Inc.
Nasdaq ODT Odonate Therapeutics, Inc.
Nasdaq ORIC Oric Pharmaceuticals, Inc.
Nasdaq OVID Ovid Therapeutics Inc.
Nasdaq PAHC Phibro Animal Health Corporation
Nasdaq PAND Pandion Therapeutics Inc.
Nasdaq PASG Passage Bio, Inc.
Nasdaq PCVX Vaxcyte, Inc.
Nasdaq PLRX Pliant Therapeutics, Inc.
Nasdaq PRTK Paratek Pharmaceuticals, Inc.
Nasdaq PRVB Provention Bio, Inc.
Nasdaq PSTX Poseida Therapeutics, Inc.
Nasdaq RAPT RAPT Therapeutics, Inc.
Nasdaq RDHL Redhill Biopharma Ltd.
Nasdaq REPL Replimune Group, Inc.
Nasdaq RLAY Relay Therapeutics, Inc.
Nasdaq RLMD Relmada Therapeutics, Inc.
Nasdaq RNA Avidity Biosciences, Inc.
Nasdaq RPRX Royalty Pharma plc
Nasdaq RPTX Repare Therapeutics Inc.
Nasdaq RVMD Revolution Medicines, Inc.
Nasdaq SELB Selecta Biosciences, Inc.
Nasdaq SMMT Summit Therapeutics Inc.
Nasdaq SNDX Syndax Pharmaceuticals, Inc.
Nasdaq SPRO Spero Therapeutics, Inc.
Nasdaq STRO Sutro Biopharma, Inc.
Nasdaq SURF Surface Oncology, Inc.
Nasdaq SWTX SpringWorks Therapeutics, Inc.
Nasdaq TCRR TCR2 Therapeutics Inc.
Nasdaq VIE Viela Bio, Inc.
Nasdaq VIR Vir Biotechnology, Inc.
Nasdaq VSTM Verastem, Inc.
Nasdaq VYNE VYNE Therapeutics Inc.
Nasdaq XENE Xenon Pharmaceuticals Inc.
Nasdaq ZIOP ZIOPHARM Oncology Inc
Nasdaq ZNTL Zentalis Pharmaceuticals, Inc.
Was ist den mit der Meldung das Moderna in Nasdaq100 gelistet werden soll.Ist das im Sand verlaufen oder gibts was neues...
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: themenfremder Inhalt
Die Schweiz testet auch.Wenn das alles Zum positiven ausläuft sollte die 200$ Marke kein Problem sein.Das wichtigste ist natürlich die FDA-Zulassung.
https://www.aerzteblatt.de/nachrichten/118371/Schweizer-Arzn…
https://www.aerzteblatt.de/nachrichten/118371/Schweizer-Arzn…
Durchsuchen
Moderna
